Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

PURPOSE: To determine the pharmacokinetics (PK), maximum tolerated dose (MTD), safety, and antitumor activity of an oral formulation of rigosertib, a dual phosphoinositide 3-kinase (PI3K) and polo-like kinase 1 (Plk1) pathway inhibitor, in patients with advanced solid malignancies. EXPERIMENTAL DESI...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bowles, Daniel W., Diamond, Jennifer R., Lam, Elaine T., Weekes, Colin D., Astling, David P., Anderson, Ryan T., Leong, Stephen, Gore, Lia, Varella-Garcia, Marileila, Vogler, Brian W., Keysar, Stephen B., Freas, Elizabeth, Aisner, Dara L., Ren, Chen, Tan, Aik-Chook, Wilhelm, Francois, Maniar, Manoj, Eckhardt, S. Gail, Messersmith, Wells A., Jimeno, Antonio
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4160109/
https://ncbi.nlm.nih.gov/pubmed/24493827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-2506
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados